Slide1PresentedByNicolaMagriniat2019ASCOAnnualMeeting
Slide2PresentedByNicolaMagriniat2019ASCOAnnualMeeting
ConflictofinterestsPresentedByNicolaMagriniat2019ASCOAnnualMeeting
EssentialMedicinesforcancerbr/ContentsofthepresentationPresentedByNicolaMagriniat2019ASCOAnnualMeeting
EML2017PresentedByNicolaMagriniat2019ASCOAnnualMeeting
AquotationPresentedByNicolaMagriniat2019ASCOAnnualMeeting
EMLsince1977:anearlyevidence-basedadopterPresentedByNicolaMagriniat2019ASCOAnnualMeeting
GlobalaccesstoEssentialMedicinesforcancerbr/ContentsofthepresentationPresentedByNicolaMagriniat2019ASCOAnnualMeeting
Slide9PresentedByNicolaMagriniat2019ASCOAnnualMeeting
MethodologytoupdateEMLin2015PresentedByNicolaMagriniat2019ASCOAnnualMeeting
CancerconsideredinEML2015:22+12PresentedByNicolaMagriniat2019ASCOAnnualMeeting
MeasurementsofBenefit–Example1PresentedByNicolaMagriniat2019ASCOAnnualMeeting
MeasurementsofBenefit–Example2PresentedByNicolaMagriniat2019ASCOAnnualMeeting
NewEMLcancermedicinesmaincriterion:br/magnitudeofabsolutebenefitsPresentedByNicolaMagriniat2019ASCOAnnualMeeting
LanceteditorialOctober24,2015PresentedByNicolaMagriniat2019ASCOAnnualMeeting
EML2017cancerupdatePresentedByNicolaMagriniat2019ASCOAnnualMeeting
EMLcancerdrugs:2015and2017PresentedByNicolaMagriniat2019ASCOAnnualMeeting
Slide18PresentedByNicolaMagriniat2019ASCOAnnualMeeting
2019EMLcancerupdate:br/mainapplicationsPresentedByNicolaMagriniat2019ASCOAnnualMeeting
GlobalaccesstoEssentialMedicinesforcancerbr/ContentsofthepresentationPresentedByNicolaMagriniat2019ASCOAnnualMeeting
Slide21PresentedByNicolaMagriniat2019ASCOAnnualMeeting
Slide22PresentedByNicolaMagriniat2019ASCOAnnualMeeting
CommentstotheproposedcriteriaPresentedByNicolaMagriniat2019